Journal
CURRENT OPINION IN INFECTIOUS DISEASES
Volume 26, Issue 6, Pages 538-544Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0000000000000004
Keywords
aerosolized antibiotics; pharmacokinetics; ventilator-associated pneumonia
Categories
Funding
- NIAID
- Barnes-Jewish Hospital Foundation
- Cardeas Pharma Corp.
- CareFusion
- Infectious Diseases Society of America
- Johnson Johnson
Ask authors/readers for more resources
Purpose of reviewThe increasing rate of ventilator-associated pneumonia (VAP) caused by multidrug-resistant pathogens warrants the development of new treatment strategies. Carefully engineered delivery systems are undergoing evaluation to test the hypothesis that aerosolized administration of antibiotics will provide high local concentrations and fast clearance, which in turn may improve efficacy and decrease the risk of microbial resistance.Recent findingsRecent studies indicate that aerosolized delivery systems for specially formulated antibiotics yield high local concentrations with rapid clearance and low systemic exposure. Preliminary clinical studies reveal that aerosolized delivery of antibiotics is well tolerated and active, when combined with intravenous antibiotics. No single aerosolized antibiotic is likely to provide broad-spectrum activity against both Gram-negative and Gram-positive bacteria.SummaryLarge multicenter trials are needed to determine whether preliminary findings will translate to improved clinical activity and decreased microbial resistance in VAP patients, and to optimize the use of aerosolized antibiotics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available